{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:46:03Z","timestamp":1790358363641,"version":"4.1.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"\n Importance<\/jats:title>\n Hidradenitis suppurativa (HS) is a chronic inflammatory dermatological disease with prevalence estimates ranging from 0.1% to 0.5% in clinical settings to 1% to 2% in general populations. While tertiary care data show that 22% of patients progress to severe disease within 2 years, estimates of disease development outside the hospital setting remain unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate HS development in a non\u2212hospital-based setting and to identify baseline factors associated with remission and progression to severe disease in the community.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective cohort study used 10-year follow-up data on HS disease severity among a municipality-based cohort identified via a questionnaire in the Danish General Suburban Population Study conducted from 2010 to 2013. Disease severity (mild, moderate, severe) was determined using a modified Hurley score. Progression (severe disease at follow-up) and remission (no active HS symptoms for 6 months or longer at follow-up) rates were calculated by severity level. Separate Cox proportional hazard regression analyses explored whether baseline demographic variables associated with disease severity at follow-up in 2023 could be used to estimate changes in disease severity. Data analysis was performed from March 2024 to September 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n HS remission and progression rates across baseline severity groups as determined at follow-up in January to February 2023. Measures included baseline HS disease severity, body mass index, smoking history, employment status, and number of anatomical areas with active lesions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The analysis included 107 patients with HS (mean [SD] age, 47.1 [8.8] years; 88 female [82.2%] and 19 male [17.8%] individuals). At baseline, 57 patients (53.3%) had mild, 20 (18.7%) had moderate, and 30 (28.0%) had severe disease. During the follow-up period, 16.9% of patients with nonsevere disease progressed (13.0% to severe disease), while 71.0% of all patients experienced regression (63.6% to full remission). Stratified by baseline severity, 73.7%, 60.0%, and 46.7% of patients with mild, moderate, and severe disease, respectively, experienced full remission. Cox regression analyses did not reveal any baseline demographic factors capable of predicting disease development at follow-up.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that estimates from hospital-based cohorts likely overstate HS disease progression and underestimate its remission. In this community-based cohort, HS progression to severe disease was 10.4 times lower and rates of HS remission were 3.8 times higher than reported within hospitals, suggesting a more favorable disease course than previously reported.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.4700","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:31:35Z","timestamp":1764174695000},"page":"60","source":"Crossref","is-referenced-by-count":6,"title":["Hidradenitis Suppurativa Remission and Progression in a Community Setting"],"prefix":"10.1001","volume":"162","author":[{"given":"Rune","family":"Kj\u00e6rsgaard Andersen","sequence":"first","affiliation":[{"name":"PHOENIX Research Center, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Department of Immunology and Microbiology, Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Dermatology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Kranker","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zealand University Hospital, Roskilde, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Birger V.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Clinical Immunology, Zealand University Hospital, K\u00f8ge, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv","family":"Eidsmo","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark"},{"name":"Division of DermatoVenerology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Medicinsk enhet Gastro, Hud, Reuma, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B. E.","family":"Jemec","sequence":"additional","affiliation":[{"name":"PHOENIX Research Center, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ellervik","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Clinical Biochemistry, Zealand University Hospital, K\u00f8ge, Denmark"},{"name":"Department of Laboratory Medicine, Boston Children\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte M. L.","family":"Saunte","sequence":"additional","affiliation":[{"name":"PHOENIX Research Center, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"dbr250012r1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice-hidradenitis suppurativa.","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"dbr250012r2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad530","article-title":"Initial steps towards developing a predictive algorithm of disease progression for hidradenitis suppurativa: results from a Cox proportional hazard regression analysis on disease progression amongst a cohort of 335 Danish patients with hidradenitis suppurativa.","author":"Kj\u00e6rsgaard Andersen","year":"2024","journal-title":"Br J Dermatol"},{"key":"dbr250012r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.2373","article-title":"Prevalence of hidradenitis suppurativa: a meta-analysis of Global Hidradenitis Suppurativa Atlas Studies.","author":"Bouazzi","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"4","key":"dbr250012r4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jaad.2013.11.014","article-title":"The prevalence of metabolic syndrome in patients with hidradenitis suppurativa.","volume":"70","author":"Gold","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"dbr250012r5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/ced.14478","article-title":"Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity.","volume":"46","author":"\u00d6zkur","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"dbr250012r6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/jdv.17857","article-title":"Incidence and remission rates of self-reported hidradenitis suppurativa-a prospective cohort study conducted in Danish blood donors.","volume":"36","author":"Kjaersgaard Andersen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"dbr250012r7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","article-title":"Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system.","volume":"236","author":"Kokolakis","year":"2020","journal-title":"Dermatology"},{"issue":"9","key":"dbr250012r8","first-page":"A4693","article-title":"Study design, participation and characteristics of the Danish General Suburban Population Study.","volume":"60","author":"Bergholdt","year":"2013","journal-title":"Dan Med J"},{"issue":"1","key":"dbr250012r9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjd.15778","article-title":"Hidradenitis suppurativa and electrocardiographic changes: a cross-sectional population study.","volume":"178","author":"Juhl","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"dbr250012r11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/bjd.12787","article-title":"The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa.","volume":"170","author":"Vinding","year":"2014","journal-title":"Br J Dermatol"},{"issue":"12","key":"dbr250012r12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/jamadermatol.2014.1165","article-title":"Association of metabolic syndrome and hidradenitis suppurativa.","volume":"150","author":"Miller","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"4","key":"dbr250012r13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjd.13090","article-title":"Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study.","volume":"171","author":"Kromann","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"dbr250012r14","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem.","volume":"173","author":"Saunte","year":"2015","journal-title":"Br J Dermatol"},{"key":"dbr250012r10","unstructured":"Kj\u00e6rsgaard Andersen? R, Larsen? MK, Pedersen? OBV, . Danish questionnaire for the The Danish General Suburban Population Study (GESUS) follow-up study on hidradenitis suppurativa prevalence and disease development. Accessed November 4, 2025. Mendeley Data, V3. doi:10.17632\/j6szpjxtw5.3"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2841755\/jamadermatology_kjrsgaard_andersen_2025_br_250012_1768581578.42467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:00:49Z","timestamp":1769011249000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2841755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.4700","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}